Catalyst Pharmaceuticals (NASDAQ:CPRX) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.07, Bloomberg Earnings reports. The firm had revenue of $28.84 million for the quarter, compared to the consensus estimate of $17.99 million. The firm’s revenue was up 2883900.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.06) EPS.
CPRX traded up $0.08 during trading on Wednesday, reaching $5.13. 1,394,736 shares of the company were exchanged, compared to its average volume of 1,865,701. The company has a 50-day simple moving average of $4.24. The stock has a market cap of $518.36 million, a P/E ratio of -15.55 and a beta of 2.60. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.07 and a current ratio of 6.08. Catalyst Pharmaceuticals has a 12-month low of $1.85 and a 12-month high of $6.16.
CPRX has been the subject of several research reports. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 price target for the company in a research note on Wednesday, July 31st. HC Wainwright set a $9.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 14th. BidaskClub upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday. ValuEngine cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 8th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $10.00 price objective on shares of Catalyst Pharmaceuticals in a report on Tuesday, May 7th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Catalyst Pharmaceuticals has an average rating of “Buy” and a consensus price target of $7.65.
In related news, CEO Patrick J. Mcenany acquired 25,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were acquired at an average price of $3.23 per share, with a total value of $80,750.00. Following the acquisition, the chief executive officer now owns 4,762,693 shares of the company’s stock, valued at approximately $15,383,498.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.70% of the company’s stock.
Several large investors have recently added to or reduced their stakes in CPRX. Kennedy Capital Management Inc. purchased a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at about $5,099,000. BlackRock Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 11.5% in the 4th quarter. BlackRock Inc. now owns 6,970,873 shares of the biopharmaceutical company’s stock valued at $13,384,000 after acquiring an additional 719,093 shares in the last quarter. EAM Global Investors LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 1st quarter valued at about $1,409,000. Swiss National Bank purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at about $661,000. Finally, Chicago Equity Partners LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at about $627,000. 59.72% of the stock is currently owned by hedge funds and other institutional investors.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.